Navigation Links
Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
Date:11/22/2011

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, but are not limited to, statements regarding the expected net proceeds from the offering.  Actual results may differ materially from those set forth in this press release due to the risks and uncertainties, including, without limitation, those associated with Cadence's actual offering expenses, as well as those inherent in Cadence's business and finances in general, including the risks detailed in Cadence's prior press releases as well as in Cadence's periodic and other public filings with the SEC.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.  

 Contact:

William R. LaRue

Kelli France 

SVP & Chief Financial Officer

Media Relations 

Cadence Pharmaceuticals, Inc.

WCG 

Phone: 858-436-1400

Phone: 415-946-1076 


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The global ... of products, methods, applications, end users, and geographies. ... in the microbial identification market. This favorable growth ... (per test) and the time required for microbial ... technological advancements. Furthermore, genotypic methods have high applications ...
(Date:7/29/2014)... BASKING RIDGE, N.J. , July 29, 2014 /PRNewswire/ ... a biopharmaceutical company focused on the Phase 3 clinical ... first-in-class, actively controllable antithrombotic drug system, today announced that ... webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. ... and corporate highlights. Interested participants and investors ...
(Date:7/29/2014)...  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... third quarter 2014 after the market close on Monday, ... host a conference call for investors on Tuesday, August ... Eastern Time). Investors may access the live call by ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... Reported in 4Q 2007 -, LA JOLLA, ... TPTX ) today announced that it has completed,enrollment ... for the treatment,of acute migraine headache. Tezampanel is ... non-vascular and non-serotonergic,approach to the management of pain ...
... 3 trial of Genasense(R) seeks to confirm benefit in melanoma -- ... Company regains compliance for NASDAQ Global Markets listing; Genta common stock ... program for Genasense will continue ... during Phase 3 trial ...
Cached Medicine Technology:TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 2TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 3TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 8
(Date:7/30/2014)... Computer Resources of America, Inc. (CRA), an ... City, has been awarded the contract to rewire the ... large global bank. The bank is a global leader ... of CRA said, “Being awarded this contract with our ... what has already been a successful and deep relationship. ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review ... for men who want to discover how to increase their ... within a few months. Inside this book, learners will discover ... and avoid the aches and pains. , Vkool reveals in ... learners the reason why stretching and warming up is so ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... VisitandCare.com today announced that several ... the company’s exclusive network to help couples struggling with ... — as top fertility clinics in Spain, Switzerland, Greece, ... and successful IVF treatments. , The exclusive selection of ... by professionals at VisitandCare.com. The goal is to connect ...
(Date:7/29/2014)... 2014 Phytceramides are a natural anti-aging tool for ... new book. , Today is the last day to nab a ... Best . The book is also sold in hard copy. , ... that Phytoceramides were so new and very unknown in ... book now," says Kathy Heshelow, founder of Sublime Beauty®. "It is ...
Breaking Medicine News(10 mins):Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3
... Services, Treatment and Prevention Available--MINNEAPOLIS, April 29 ... health care centers in the United States, is ... flu (H1N1) and provide rapid testing services, treatment ... medically appropriate. MinuteClinic is coordinating with local ...
... 29 Grupo Aeroportuario del Sureste, S.A.B. de C.V. ... first privatized airport group in Mexico and operator of Cancun ... today that on April 26, 2009 the Mexican Secretary of ... in Mexico. On April 28, 2009 the World Health Organization ...
... BOTHELL, Wash., April 29 SCOLR Pharma, Inc. (NYSE Alternext ... financial results on Friday, May 1, 2009, at 8:30 a.m. ... Pharma, will host the conference call at 11:30 a.m. Eastern, ... other interested parties may participate in the conference call by ...
... Survey finds many cities have dangerously high levels of pollution ... of the nation,s population, 186.1 million people to be exact, ... air pollution, new research shows. , "Six out of ten ... the emergency room, to shape how kids, lungs develop and ...
... 2009 Relationships are difficult and most of us probably ... when discussing stressful issues, like home finances, is an impossible ... take the "edge" off these discussions? The biology of ... research on social cognition conducted in animals is now informing ...
... Michigan physicians are the first in the nation ... through a new partnership announced today by the American ... with Compuware,s Covisint subsidiary. This partnership builds on ... the AMA announced its agreement with Covisint to develop ...
Cached Medicine News:Health News:MinuteClinic is Educating Consumers About Swine Flu 2Health News:MinuteClinic is Educating Consumers About Swine Flu 3Health News:SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern 2Health News:More Than Half of Americans Living with Dirty Air 2Health News:More Than Half of Americans Living with Dirty Air 3Health News:Oxytocin: Love potion #1? 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... qualitative differential detection of ... and an antigen that is ... of malaria:plasmodium falciparum (P.f), plasmodium ... and Plasmodium malariae (P.m) in ...
Medicine Products: